Attention Deficit Hyperactivity Disorder (ADHD) in Children under Age 6

Level 0

Conduct comprehensive assessment and provide psychoeducation about ADHD, including clearly defined treatment expectations. Consider co-morbid developmental language disorder, Specific Learning Disorder or Autism Spectrum Disorder (ASD).

Facilitate family engagement, psychoeducation about ADHD (evidence-based behavioral interventions, educational interventions, and medication treatments), and treatment preference assessment. Treatment response should be monitored using rating scales and appropriate health (vital signs, height, weight) and safety assessments. Refer to *General Principles of Practice Regarding the Use of Psychotropic Medications in Children under Age 6* on page 5.

Level 1

Provide parent management/skills training or other behavioral intervention at home and/or school for a minimum of 12 weeks.

Level 2

Initiate monotherapy with immediate-release methylphenidate formulation.

Level 3

If methylphenidate is unsuccessful, could consider monotherapy with atomoxetine (caution: child must be able to swallow medication whole).

Level 4

Consider immediate-release amphetamine formulations which have FDA indication for ages 3 to 5 years old but limited clinical trial evidence base. May also consider alpha-2 agonists, but no published data are available.

- After 6 months of sustained improvement on any effective medication treatment, taper in order to determine the lowest effective dose and possibility of discontinuation.

Level 5

If immediate-release monotherapy has failed, may consider extended-release stimulant medication within special dosing guidelines for preschoolers.

Not Recommended:

- Antipsychotic medication to treat core symptoms of ADHD.
- Concurrent use of two or more alpha-2 agonists.

Table 3.

ADHD Medication Treatment for Children under Age 6	
Drug Name	**Starting Dose Recommendation**
Methylphenidate and Amphetamine preparations	
Short-acting	
Methylphenidate[1]: ***Immediate Release:*** Ritalin®, Methylin®, Methylin® Chewable Tablets, Methylin® Oral Solution	1.25 mg tid – titrate as needed to doses not exceeding 1 mg/kg/day. *Recommendations extrapolated from the Preschool ADHD Treatment Study (PATS).*
Amphetamine[2]: ***Immediate Release:*** Mixed amphetamine salts (Adderall®), d-amphetamine (Zenzedi®, ProCentra® Oral Solution); d- & l-amphetamine (Evekeo®)	2.5 mg/day – titrate as needed to doses not exceeding 0.5 mg/kg/day. *Amphetamine target dose is generally one- half to two-thirds of methylphenidate dose.*
Selective norepinephrine inhibitor	
Atomoxetine[3] (Strattera®)	10 mg/day – titrate as needed to doses not to exceed 1.4 mg/kg/day. *Recommendations extrapolated from the Kratochvil et al. 2011 study.*
Alpha-2 Agonists[4]	
Alpha-2 Agonists[4]: **Clonidine** (Catapres®, KAPVAY®) **Guanfacine** (Tenex®, Intuniv®)	Starting dose not to exceed: 0.05 mg/day *(clonidine)* 0.5 mg/day *(guanfacine)* Monitor carefully for excessive sedation, increased irritability. *Recommendations based on expert opinion.*

Notes:

[1] No FDA indication for children younger than 6 years old; based on Preschool ADHD Treatment Study results (Greenhill et al., 2006).

[2] FDA indication for ADHD treatment of children 3-5 years old, but no clinical trial study results available.

[3] No FDA indication for children younger than 6 years old; based on Kratochvil et al., 2011.

[4] No FDA indication for ADHD except guanfacine extended-release (Intuniv®) and clonidine extended-release (KAPAVY®) in children 6 years and older; no clinical trial study results available for alpha-2 agonist use for ADHD in children below age 6 years old.

There is no new data on extended-release stimulants in preschoolers, but the 2007 American Academy of Child and Adolescent Psychiatry guideline algorithm included extended-release formulations to address compliance concerns (Pliszka et al., 2007).

Attention Deficit Hyperactivity Disorder (ADHD) in Children and Adolescents Ages 6 to 17 Years Old

Level 0

Comprehensive assessment including a detailed developmental, educational, and symptom history. Recommended rating scales:

- ADHD Rating Scale-IV
- Vanderbilt ADHD Diagnostic Parent and Teacher Rating Scales

Links to rating scales available at ***http://medicaidmentalhealth.org/***.

Facilitate family engagement, psychoeducation about ADHD (evidence-based behavior and medication treatments, and educational interventions), and assess treatment preference.

Ensure that treatment response is monitored using rating scales and appropriate health (vital signs, height and weight) and safety assessments.

Level 1

- Psychostimulant monotherapy (methylphenidate class or amphetamine class, either immediate-release or extended-release). If first choice is ineffective, try monotherapy with another stimulant (Refer to Tables 4 and 5 of ADHD medications on pages 19–22). If supplementation of extended-release with immediate-release psychostimulant required for sufficient coverage, stay within same drug class.

  OR

- Extended-release alpha-2 agonist monotherapy.

Level 2

- Combination of extended-release alpha-2 agonist with psychostimulant.

  OR

- Atomoxetine monotherapy.

Level 3

Immediate-release alpha-2 agonist (as monotherapy or combination with other ADHD medication classes).

Level 4

Diagnostic reconsideration if none of the above agents result in satisfactory treatment. Consider bupropion or tricyclic antidepressant. Despite limited evidence, these medications may be considered.

Desipramine is not recommended due to safety concerns.

Not Recommended:

- Antipsychotic medication to treat core symptoms of ADHD.
- Concurrent use of two or more alpha-2 agonists.
- Concurrent use of two different stimulant classes.

Table 4.

FDA Approved ADHD Medications in Children and Adolescents Ages 6 to 17 Years Old				
Generic Class/ Brand Name	**Typical Starting Dose**	**FDA Max Dose/Day**	**Off-Label Max Dose/Day**	**Comments**
Methylphenidate preparations				
Immediate-Release				Immediate-release stimulants are often used as initial treatment in children (<16 kg), but have disadvantage of b.i.d. – t.i.d. dosing to control symptoms throughout the day.
Focalin® (dexmethylphenidate hcl tablet)	2.5 mg bid	20 mg	50 mg	
Ritalin® (methylphenidate hcl tablet)	5 mg bid	60 mg	>50 kg: 100 mg	
Methylin® Solution (methylphenidate hcl oral solution)	5 mg bid	60 mg	>50 kg: 100 mg	
Methylphenidate Chewable (methylphenidate hcl chewable tablet)	5 mg bid	60 mg	>50 kg: 100 mg	
Intermediate-Release				Longer acting stimulants offer greater convenience, confidentiality, and compliance with single daily dosing but may have greater problematic effects on evening appetite and sleep.
Metadate ER® (methylphenidate hcl extended-release tablets)	10 mg qam	60 mg	>50 kg: 100 mg	
Metadate CD® (methlypheidate hcl extended-release capsule)	10 mg qam	60 mg	>50 kg: 100 mg	
Ritalin LA® (methylphenidate hcl extended-release tablet)	20 mg qam	60 mg	>50 kg: 100 mg	
Notes: *Ritalin LA 60 mg (specific brand and dose) and Ritalin SR were discontinued for reasons other than safety and effectiveness. Ritalin LA brand drug is still available in 10 mg, 20 mg, 30 mg, and 40 mg capsules (i.e., doses other than 60 mg). The generic methylphenidate extended-release capsule is available in all doses, including 60 mg.*				

Table 4 *(continued)*.

FDA Approved ADHD Medications in Children and Adolescents Ages 6 to 17 Years Old				
Generic Class/ Brand Name	**Typical Starting Dose**	**FDA Max Dose/Day**	**Off-Label Max Dose/Day**	**Comments**
Extended-Release				
Aptensio XR® (methylphenidate hcl extended-release capsule)	Begin with 10 mg qam then titrate by 10 mg at weekly intervals	60 mg	>50 kg: 100 mg	Aptensio XR®,Metadate CD®, Ritalin LA® and Focalin XR® capsules may be opened and sprinkled on soft food for immediate consumption. Beads should not be crushed or chewed. Concerta® should not be crushed, chewed, or broken. Swallow whole with liquids. Non-absorbable tablet shell does not dissolve and may be seen in stool. This is normal. Qillivant XR® is an extended-release once-daily suspension. QuilliChew ER® can be broken in half.
Cotempla XR-ODT® (methylphenidate tablet, orally disintegrating)	Begin with 17.3 mg qam then titrate up by 8.6 mg to 17.3 mg weekly	51.8 mg	Not yet known	
Concerta® (methylphenidate extended-release tablet)	18 mg qam	72 mg	>50 kg: 108 mg	
Daytrana® patch (methylphenidate transdermal system)	Begin with 10 mg patch daily, then titrate up by patch strength 5 mg qam	30 mg	Not yet known	
Focalin XR® (dexmethylphenidate hcl extended-release capsule)	5 mg qam	30 mg	50 mg	
Quillivant XR® (methylphenidate hcl extended-release oral suspension)	Begin with 20 mg qam, then titrate up by 10-20 mg at weekly intervals	60 mg	>50 kg: 100 mg	
QuilliChew ER® (methylphenidate hcl extended-release chewable tablet)	Begin with 20 mg qam then titrate in increments of 10 mg, 15 mg or 20 mg at weekly intervals	60 mg	>50 kg: 100 mg	

Table 5.

FDA Approved ADHD Medications in Children and Adolescents Ages 6 to 17 Years Old				
Generic Class/ Brand Name	**Typical Starting Dose**	**FDA Max Dose/Day**	**Off-Label Max Dose/Day**	**Comments**
Amphetamine preparations				
Immediate-Release				Immediate-release stimulants are often used as initial treatment in children (<16 kg) but have disadvantage of b.i.d. – t.i.d. dosing to control symptoms throughout the day. Note that Adderall®, Procentra Oral Solution®, Evekeo®, and Zenzedi® have the same dosing recommendations.
Adderall® (amphetamine mixed salts tablet)	5 mg daily – bid	40 mg	>50 kg: 60 mg	
Procentra Oral Solution® (d-amphetamine oral solution)	5 mg daily – bid	40 mg	>50 kg: 60 mg	
Evekeo® (d- and l-amphetamine tablet)	5 mg daily – bid	40 mg	>50 kg: 60 mg	
Zenzedi® (d-amphetamine tablet)	5 mg daily – bid	40 mg	>50 kg: 60 mg	

Table 5 *(continued)*.

FDA Approved ADHD Medications in Children and Adolescents Ages 6 to 17 Years Old				
Generic Class/ Brand Name	**Typical Starting Dose**	**FDA Max Dose/Day**	**Off-Label Max Dose/Day**	**Comments**
Extended-Release				Longer acting stimulants offer greater convenience, confidentiality, and compliance with single daily dosing but may have greater problematic effects on evening appetite and sleep.
Dexedrine Spansule® (dextroamphetamine sulfate extended-release capsule)	5–10 mg daily to twice per day	40 mg	Not yet known	
Adderall XR® (amphetamine extended-release mixed salts capsule)	10 mg daily	6–12 years: 30 mg 13–17 years: 20 mg	>50 kg: 60 mg	Adderall XR® capsule may be opened and sprinkled on soft foods.
Vyvanse® (lisdexamfetamine capsule)	20–30 mg daily	70 mg	Not yet known	Vyvanse® capsule can be opened and mixed with yogurt, water or orange juice. Vyvanse® Chewables must be chewed thoroughly before swallowing. Do not divide single doses.
Vyvanse® (lisdexamfetamine chewables)	20–30 mg daily	70 mg	Not yet known	
Dyanavel XR® 2.5mg/mL (amphetamine extended-release oral suspension)	2.5 to 5 mg daily	20 mg	Not yet known	For Dyanavel XR® do not substitute for other amphetamine products on mg-per-mg basis.
Adzenys ER® (d- and l-amphetamine oral suspension, extended-release	6.3 mg qam unless switched from Adderall XR (Refer to conversion schedule)	6–12 years: 18.8 mg 13–17 years: 12.5 mg	Not yet known	For Adzenys®, do not substitute for other amphetamine products on mg-per-mg basis. For children and adolescents on Adderall XR®, specific starting doses corresponding to Adderall XR® doses are recommended, ranging from 3.1 mg of Adzenys® (for those on 5 mg of Adderall XR®) to 18.8 mg of Adzenys® (for those on 30 mg Adderall XR®).
Adzenys XR-ODT® (amphetamine extended-release orally disintegrating tablet)	6.3 mg qam unless switched from Adderall XR (Refer to conversion schedule)	6–12 years: 18.8 mg 13–17 years: 12.5 mg	Not yet known	

Table 6.

FDA Approved ADHD Medications in Children and Adolescents Ages 6 to 17 Years Old				
Generic Class/ Brand Name	**Typical Starting Dose**	**FDA Max Dose/Day**	**Off-Label Max Dose/Day**	**Comments**
Selective norepinephrine reuptake inhibitor				
Strattera® (atomoxetine)	< 70 kg: 0.5 mg/kg/day for 4 days; then 1 mg/kg/day for 4 days; then 1.2 mg/kg/day	Lesser of 1.4 mg/kg or 100 mg	Lesser of 1.8 mg/kg or 100 mg	Not a Schedule II medication. Consider if active substance abuse or severe side effects of stimulants (mood lability, tics). Give qam or divided doses b.i.d. (for effects on late evening behavior). Do not open capsule; must be swallowed whole. Monitor closely for suicidal thinking and behavior, clinical worsening, or unusual changes in behavior.
Alpha- adrenergic agonists				
Intuniv® (guanfacine ER)	1 mg daily then titrate up by 1 mg increments once per week	Lesser of 0.12 mg/kg or 4 mg daily (6-12 years) 7 mg daily (13-17 years)	Lesser of 0.17 mg/kg or 4 mg daily (6-12 years) 7 mg daily (13-17 years)	Not a Schedule II medication. Sedation, somnolence, and fatigue are common and tend to decline over time. Consider baseline electrocardiogram (EKG) before starting. Tablets should not be crushed, chewed, or broken before swallowing because this will increase the rate of release.
KAPVAY® (clonidine ER)	0.1 mg/day at bedtime	0.4 mg/day in divided doses of 0.2 mg bid	0.4 mg/day	Do not administer with high fat meals due to increased exposure. May not see effects for 4-6 weeks. Review personal and family cardiovascular history. Do not abruptly discontinue. Taper the daily dose of Intuniv by no more than 1 mg, and that of Kapvay® by no more than 0.1 mg every 3 to 7 days to avoid rebound hypertension.

Table 7.

ADHD Medications NOT FDA APPROVED in Children and Adolescents Ages 6 to 17 Years Old			
Generic Class/ Brand Name	**Typical Starting Dose**	**Max Dose/Day**	**Comments**
Alpha- adrenergic agonists			
Catapres® (clonidine)	<45 kg: 0.05 mg nightly; titrate in 0.05 mg increments two times per day, three times per day, or four times per day. >45 kg: 0.1 mg nightly; titrate in 1 mg increments two times per day, three times per day, or four times per day.	27–40.5 kg: 0.2 mg 40.5–45 kg: 0.3 mg >45 kg: 0.4 mg	The following applies to both alpha-2 adrenergic agonists: - May be used alone or as adjuvant to another medication class for ADHD. - Do not combine different alpha-2 adrenergic agents with each other - Effective for inattention, impulsivity and hyperactivity; modulating mood level; tics worsening from stimulants; sleep disturbances. Taper the daily dose of clonidine by no more than 0.1 mg every 3 to 7 days to avoid rebound hypertension.
Tenex® (guanfacine)	< 45 kg: 0.5 mg nightly; titrate in 0.5 mg increments two times per day, three times per day, or four times per day. >45 kg: 1 mg nightly; titrate in 1 mg increments. May dose increments two times per day, three times per day, or four times per day.	27–40.5 kg: 2 mg 40.5.–45 kg: 3 mg >45 kg: 4 mg	May not see effects for 4-6 weeks. Review personal and family cardiovascular history. Consider pre-treatment EKG. Taper the daily dose of guanfacine by no more than 1 mg every 3 to 7 days to avoid rebound hypertension.

Table 7 *(continued)*.

ADHD Medications NOT FDA APPROVED in Children and Adolescents Ages 6 to 17 Years Old			
Generic Class/ Brand Name	**Typical Starting Dose**	**Max Dose/Day**	**Comments**
Antidepressants			
Wellbutrin®† (bupropion)	Lesser of 3 mg/kg/day or 150 mg/day (dosed as 75 mg bid)	Lesser of 6 mg/kg or 300 mg/day. Dose should not exceed 150 mg per dose.	Lowers seizure threshold; contraindicated if current seizure disorder, anorexia nervosa or bulimia nervosa. Usually given in divided doses, b.i.d. or t.i.d. for children and adolescents, for both safety and efficacy.
Wellbutrin SR®† (bupropion SR)	Same as above	150 mg per dose or 400 mg/day	Same as above
Wellbutrin XL®† (bupropion XL)	Not recommended	Not recommended	Not recommended
Tofranil® (imipramine)	1 mg/kg/day	Lesser of 4 mg/kg or 200 mg	Obtain baseline EKG before starting imipramine.
Pamelor® Aventil® (nortriptyline)	0.5 mg/kg/day	Lesser of 2 mg/kg or 100 mg	Obtain baseline EKG before starting nortriptyline.

***Note:** Extended-release formulations of clonidine (Kapvay) and guanfacine (Intuniv) are FDA-approved ADHD medications in children and adolescents 6-17 years old, but immediate-release formulations of clonidine (Catapres) and guanfacine (Tenex) are not FDA-approved for ADHD.*

†Bupropion and bupropion SR have more data on off-label use than bupropion XL. Bupropion XL is not recommended in children and adolescents as the safety and efficacy have not been well established in this population.

For a full list of references, visit ***http://medicaidmentalhealth.org/***.

Attention Deficit Hyperactivity Disorder (ADHD) Resources

Selected Resources

Books

For Children:

- Learning To Slow Down and Pay Attention: A Book for Kids About ADHD (Nadeau, Dixon, and Beyl, 2004)
- The Girls' Guide to AD/HD (Walker, 2004)
- My Mouth is a Volcano! (Cook, 2006)
- The Survival Guide for Kids with ADD or ADHD (Taylor, 2006)
- Mrs. Gorski, I Think I Have the Wiggle Fidgets (Esham, 2008)

For Adolescents and Young Adults:

- The Girls' Guide to AD/HD (Walker, 2004)
- Delivered from Distraction: Getting the Most out of Life with Attention Deficit Disorder (Hallowell and Ratey, 2005)

For Parents:

- Driven to Distraction: Recognizing and Coping with Attention Deficit Disorder from Childhood to Adulthood (Hallowell and Ratey, 1994)
- ADHD and Teens: A Parenting Guide to Making It Through the Tough Years (Alexander-Roberts, 1995)
- The ADD and ADHD Answer Book: Professional Answers to 275 of the Top Questions Parents Ask (Ashley, 2005)
- Smart but Scattered: The Revolutionary "Executive Skills" Approach to Helping Kids Reach Their Potential (Dawson and Guare, 2009)
- Taking Charge of ADHD: The Complete, Authoritative Guide for Parents, 3rd Edition (Barkley, 2013)
- Parenting Children with ADHD: 10 Lessons that Medicine Cannot Teach (Monastra, 2014)
- How to Reach and Teach Children and Teens with ADD/ADHD: Practical Techniques, Strategies, and Interventions, 3rd Edition (Rief, 2016)

For Teachers:

- Teaching the Tiger: Handbook for individuals involved in the education of students with ADHD, Tourette's, or OCD (Dornburush and Pruitt, 1995)
- How to Reach and Teach Children and Teens with ADD/ADHD: Practical Techniques, Strategies, and Interventions, (Rief, 2016)

Attention Deficit Hyperactivity Disorder (ADHD) Resources *(continued)*

Websites

- American Academy of Child and Adolescent Psychiatry – ADHD Resource Page: https://www.aacap.org/aacap/families_and_youth/resource_centers/adhd_resource_center/Home.aspx
- Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD): https://chadd.org/
- Child Mind Institute – Teacher's Guide to ADHD in the Classroom: https://childmind.org/guide/a-teachers-guide-to-adhd-in-the-classroom/
- Mental Health America: http://www.mentalhealthamerica.net/
- National Alliance on Mental Illness (NAMI): https://www.nami.org/
- NAMI Florida: http://www.namiflorida.org/
- National Institute of Mental Health: https://www.nimh.nih.gov/index.shtml
- National Institute of Mental Health—ADHD resource page: https://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd/index.shtml

Note: Above resources and website links were updated at the time of publication.

For a full list of references, visit ***http://medicaidmentalhealth.org/***.

Treatment guidelines are available on our Program website: medicaidmentalhealth.org

If you would like hard copies of the guidelines, please email sabrinasingh@usf.edu